Oral GLP-1 data is igniting a new wave of winners. Two stocks are in
focus now. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏



 

[Morning Watchlist]

_You are receiving this email because you are subscribed to BEHIND THE
MARKETS. If you no longer wish to receive these emails,
please unsubscribe
[[link removed]] here._

_Prefer to view this content on our website? Click here.
[[link removed]]
_

-------------------------

Dear Fellow Investor,

THIS OBESITY STOCK JUST DOUBLED IN A DAY

If you’ve been following our work for any length of time, you know
we’ve been pounding the table on obesity drug stocks for a while
now. Not because it’s trendy (though it is), but because the market
opportunity is one of the biggest in modern healthcare, and the
winners could be worth tens of billions in coming years.

This week delivered a perfect reminder of why we’ve stayed locked on
this theme.

STRUCTURE THERAPEUTICS (SYM: GPCR) just put on a jaw-dropping show.
The stock basically doubled in a single day after the company released
topline Phase 2b data from its ACCESS obesity study for ALENIGLIPRON,
its once-daily oral small-molecule GLP-1 receptor agonist.

Let’s rewind for a second.

We first highlighted Structure back in late June, when it traded
around $22. Fast forward to today and shares are hovering near the
high-$60s after this surge. That’s a massive move in a short period
of time, and it didn’t happen on vibes. It happened because the data
impressed Wall Street in a category where _data is everything._

-------------------------

WHY THE ALENIGLIPRON DATA MATTERED

In the 36-week Phase 2b ACCESS trial, patients on higher doses of
aleniglipron produced PLACEBO-ADJUSTED WEIGHT LOSS IN THE LOW-TEENS,
with the top end reaching roughly the mid-teens percent in some
cohorts. Importantly, the company said weight loss SHOWED NO CLEAR
PLATEAU AT 36 WEEKS, implying there may be more runway with longer
treatment.
[[link removed]]

That “no plateau” nugget is a big deal. One of the key questions
for any obesity therapy is: _does weight loss keep compounding, or
does it stall out early?_ If Structure can show durable, continuing
loss in later-stage trials, that positions aleniglipron to compete not
only as a convenient pill, but as a potentially BEST-IN-CLASS ORAL
OPTION.

Another crowd-pleaser: SAFETY AND TOLERABILITY. Nausea and vomiting
are common across GLP-1s, and Structure did see GI side effects,
including vomiting rates that may be higher than some peers at certain
doses. But they also tested a lower starting dose that improved
tolerability—a sign management is thinking about real-world
adherence, not just headline efficacy. The company also reported a
relatively clean safety profile without major liver or cardiovascular
red flags.

Bottom line: Structure delivered the kind of combo the market wants,
STRONG EFFICACY, ORAL CONVENIENCE, AND MANAGEABLE SAFETY.

-------------------------

_Edge on the Street_

AMERICA WANTS LESS RELIANCE ON FOREIGN METALS - AND THIS NEVADA PLAY
FITS THE NATIONAL SHIFT
[[link removed]]

[nevada gradient]
[[link removed]]

The U.S. is working to reduce dependence on China and Russia for
strategic metals like copper, silver, gold, and tungsten. Guardian
Metal's recent results confirmed these metals are active in this
Nevada corridor - and its stock is up 300%+ YTD. A new explorer on the
same belt is entering early as America pivots back to domestic
supply. 
[[link removed]]

SEE HOW THIS NEVADA OPPORTUNITY ALIGNS WITH U.S. PRIORITIES.
[[link removed]]

-------------------------

WALL STREET RESPONSE: TARGETS JUMPED

Following the readout, BMO Capital raised its price target to $130 and
reiterated an outperform rating. Their rationale was straightforward:
the ACCESS data strengthened confidence in aleniglipron’s obesity
potential, pushed their estimated probability of success higher, and
supports a multi-billion-dollar peak sales outlook over the next
decade. 

When analysts start talking about multi-billion-dollar retail
potential on Phase 2b data, it tells you two things:

*
The obesity pie is enormous.

*
The market is starving for credible new entrants beyond Novo Nordisk
and Eli Lilly.

And that brings us to our next point…

ORAL GLP-1 IS THE HOLY GRAIL

Yes, injectables dominate today. Wegovy and Zepbound are household
names for a reason.

But oral obesity drugs are the next frontier. Pills are easier to
manufacture at scale, simpler for physicians to prescribe, and far
more accessible for patients who hesitate at weekly injections. If
Structure succeeds through Phase 3 and secures approval, it could open
a much wider funnel of demand.

Structure isn’t alone here, Eli Lilly’s oral GLP-1 candidate
ORFORGLIPRON is moving fast. But aleniglipron’s Phase 2b results
suggest a credible shot at competing on efficacy, and maybe even
surpassing certain dose comparisons if later data backs it up.

Remember: in obesity, PERCENTAGE POINTS MATTER. A drug that delivers a
few extra points of weight loss, _with a tolerable profile, _can win
huge share.

-------------------------

_Trade Algo_

A CRITICAL MESSAGE FOR TRADERS
[[link removed]]

This is a critical message for traders — 

Listen, OpenAI CEO Sam Altman recently spoke at the Axel Springer
Global Reporters Network in Berlin, where he said about jobs:

“I can easily imagine a world where 30-40% of the tasks that happen
in the economy today get done by AI in the not very distant future,”
said Altman.

The trend is becoming clear.

The future will belong to those people who understand how to work WITH
AI to accomplish their goals.

Those who don’t will likely fall behind.

TradeAlgo offers AI tools for retail investors to stay ahead of the
curve.

How?

TradeAlgo has developed a groundbreaking tech called Dark Flow AI. 

The tech uses artificial intelligence to scan through highly secretive
trades in dark pools and spot stocks with the biggest surge in
irregular volume.

This may boost traders’ odds of getting into trades just before
major price movements.

AS A BEHIND THE MARKETS READER, TRADEALGO WOULD LIKE TO OFFER YOU A
SPECIAL GIFT WHERE YOU CAN SIGN UP FOR THEIR SMS “DARK POOL
ALERTS” FOR FREE.
[[link removed]]

-------------------------

THE OTHER NAME STILL ON OUR RADAR: VIKING THERAPEUTICS (SYM: VKTX)

We also continue to watch VIKING THERAPEUTICS, another obesity name
we’ve highlighted many times.

VKTX is trading around the high-$30s right now, and we wouldn’t be
surprised to see another explosive move higher if its next clinical
milestones deliver.

Most recently, Viking INITIATED ITS VANQUISH PHASE 3 PROGRAM for
VK2735, its dual GLP-1/GIP agonist. The Phase 3 setup includes two
major studies—one in adults with obesity and another in
obese/overweight adults with type 2 diabetes—running 78 WEEKS and
enrolling thousands of participants.

Why is that important?

Because Phase 3 is where real value gets unlocked. Positive Phase 2
trials get you on the map. Positive Phase 3 trials get you into the
club.

And Viking isn’t going in blind. VANQUISH is built off its Phase 2
VENTURE data, where VK2735 showed DOUBLE-DIGIT WEIGHT LOSS IN JUST 13
WEEKS, with the highest cohort around the mid-teens percent. That’s
a very strong early signal.

WHAT’S NEXT FOR VIKING

Management has also been clear they’re aiming for BREADTH in
development, not a one-shot program. Alongside the weekly injectable,
they’re continuing work on:

*
an ORAL TABLET FORMULATION of VK2735

*
a potential MONTHLY MAINTENANCE REGIMEN, designed to hold weight loss
with less frequent dosing 

That kind of lifecycle strategy matters because obesity treatment
isn’t a 3-month sprint. It’s long-term disease management.
Companies that offer multiple dosing options (weekly, monthly, oral)
can capture more patients across more use cases.

DON’T IGNORE THE M&A BACKDROP

Finally, there’s still the very real possibility of a buyout wave in
obesity.

Big Pharma has _zero interest_ in missing the next mega-category.
Pfizer is a perfect example: after its internal GLP-1 attempts
stumbled, CEO Albert Bourla has been openly aggressive about
rebuilding the company’s obesity pipeline through deals. Pfizer just
spent billions acquiring Metsera and today announced another GLP-1
partnership, underscoring how serious they are about buying their way
into the market. 

That doesn’t mean Viking (or Structure) _will_ get bought tomorrow.
But it does mean high-quality mid-cap obesity developers are on the
radar of cash-rich giants who need a seat at the table.

-------------------------

_InvestorPlace Media_

WHICH STOCK WILL THE WHITE HOUSE BUY NEXT?
[[link removed]]

[investorplace photo]
[[link removed]]

INSIDERS IN WASHINGTON HAVE ALREADY BOUGHT MASSIVE STAKES IN THREE
TINY RESOURCE FIRMS, DRIVING THEM UP AS MUCH AS 200% OVERNIGHT. NOW,
THE MAN WHO RECOMMENDED MP MATERIALS BEFORE THE WHITE HOUSE BOUGHT
(MAKING 100% FOR HIS FOLLOWERS) IS NAMING THE NEXT STOCKS HE BELIEVES
THE GOVERNMENT WILL TARGET.

GET THE NAMES AND TICKERS RIGHT HERE – FREE OF CHARGE.
[[link removed]]

-------------------------

_Are there any other biotech stocks you're buying right now? What
other sectors of the market are you currently interested in? Hit
"reply" to this email and let us know your thoughts!_

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of Lexston Mining (CSE: LEXT | OTC: LEXTF). The compensation consists
of up to $5,500 and was received/will be received from i2i Marketing
Group.

This communication should not be considered as an endorsement of the
securities of adviser Lexston Mining (CSE: LEXT | OTC: LEXTF) and we
are not responsible for any errors or omissions in any information
provided about the securities of Lexston Mining (CSE: LEXT | OTC:
LEXTF) by Edge on the Street or i2i Merketing Group.

We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.

This disclosure is made as of 12/10/2025.

Behind the Markets
[[link removed]]

Unsubscribe
[[link removed]]

invisiblelink
[[link removed]]